- Specialization
- Biotechnology
- Business
- Scientific Research
- Market
Healthcareand 1 more market valuesLess
- Life Sciences
- Ecosystem
- Not applicable
- Customers
Enterprisesand 1 more customers valuesLess
- Researchers
More details
- Organization type
- Commercial Company
- Ecosystem
- Not applicable
- Business
- Scientific Research
- Specialization
- Biotechnology
- Market
- Healthcare, Life Sciences
- Customers
- Enterprises, Researchers
- Delivery models
- Not classified
- Revenue models
- Not classified
- Listing status
- Not classified
- Latest equity round
- Seed
- Reported funding amount
- Not classified
About
Signatur Biosciences is a B2B molecular-diagnostics company developing smart PCR kits and the PCRchitectur platform for hospitals, clinical laboratories, and diagnostic partners. Its tests condense complex gene-expression signatures into a single reaction on standard qPCR equipment, making precision diagnostics faster, cheaper, and more decentralized than centralized genomic testing.
Market
Signatur competes in B2B molecular diagnostics and precision oncology, initially targeting breast-cancer prognostic testing that traditionally depends on centralized genomic laboratories. Its differentiation is a decentralized, single-reaction qPCR approach that compresses complex RNA signatures onto standard hospital instruments, aiming to deliver same-day or few-day results at substantially lower material cost while preserving the clinical utility of reference-lab assays.
Ideal customers are hospitals and clinical laboratories—especially decentralized labs with standard qPCR equipment—whose clinicians and laboratory teams need rapid breast-cancer prognostic results. On the partner side, Signatur targets B2B molecular-diagnostics companies developing biomarker panels, genomic tests, or gene-expression assays.
At a Glance
Problem
Precision breast-cancer prognosis is often delivered through centralized genomic assays that can cost around $4,000, require international sample shipment, and take up to three weeks. That combination of expense, logistics, and delay leaves many women without timely information to guide treatment, particularly in regions without advanced reference laboratories. The killer use case is making prognostic testing available locally to hospitals and clinical laboratories using infrastructure they already have.
Product / Service
Signatur’s first product, OncoSignatur Breast, is a decentralized test kit under development for local breast-cancer prognostic testing. Its proprietary PCRchitectur technology condenses complex RNA or gene-expression signatures into a single streamlined qPCR reaction that runs on standard machines and fits existing hospital workflows. The intended benefit is same-day or near-term results, lower material costs—claimed to be up to 20-fold lower than conventional methods—and comparable clinical utility to reference-lab genomic assays, without requiring expensive specialized equipment.
Market
Signatur competes in precision molecular diagnostics, initially targeting the breast-cancer genomic-prognosis market. Its comparison set includes established genomic assays such as Oncotype DX, MammaPrint, EndoPredict, Prosigna Breast Cancer Assay, and Breast Cancer Index, as well as technically adjacent RT-qPCR approaches such as MammaTyper. Signatur’s differentiation is not simply another centralized gene-expression test, but a lower-cost, decentralized delivery model built around ordinary qPCR equipment.
The company appears pre-commercial rather than an established revenue-generating diagnostics provider: its own materials describe OncoSignatur Breast and the underlying technology as under development and not available for sale. It has nevertheless demonstrated meaningful financing traction, closing a $7 million seed round in May 2025 and reporting $9.9 million in total funding, intended to support product development, validation, a dedicated laboratory, team expansion, and commercialization activities. Public evidence reviewed here does not establish launched-product revenue or customer adoption.
Founders & Leadership
Funding History
Y Combinator
Innovate UK (UKRI)
The Discovery Lab of IBA (Ion Beam Applications), Noshaq
Recent News
A Signatur Biosciences company update states that the startup is establishing a new laboratory facility in Liège, Belgium, while maintaining a predominantly London-based remote workforce.
Active Roles
0No active roles right now.
Get notified when they postBusiness Model
Signatur is pursuing a pre-commercial B2B model built around partnerships with molecular-diagnostics companies and deployment of its PCR kits and platform by hospitals and clinical laboratories. Public pricing and current revenue are not disclosed; the company states that its technology and products remain under development and are not yet for sale.